Resection of thoracic and abdominal teratoma in patients after cisplatin-based chemotherapy for germ cell tumor

Late results

Patrick Loehrer, I. Mandelbaum, Siu Hui, S. Clark, Lawrence Einhorn, S. D. Williams, J. P. Donohue

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Fifty-one patients with primary testicular (N = 46) or mediastinal germ cell cancer (N = 5) were treated from April, 1975, through May, 1981, and had teratoma resected from residual disease after cisplatin-based combination chemotherapy. All patients had normal serum markers before resection of pulmonary (N = 12), mediastinal (N = 5), thoracoabdominal (N = 8), supraclavicular (N = 1) or abdominal disease (N = 25). Teratoma was classified as mature teratoma (N = 29), immature teratoma (N = 15), or immature teratoma with non-germ cell elements (N = 7). Thirty of 51 (60%) patients remain free of recurrent disease, whereas 20 patients have either recurrent carcinoma (N = 10) or teratoma (N = 10). One patient has a presumed second malignancy. After additional chemotherapy, four patients with recurrent carcinoma are alive and disease free and six have died. After an additional operation, eight of 10 patients with recurrent teratoma are long-term survivors. In four patients the initial relapse of carcinoma developed more than 2 years after therapy; in an additional patients carcinoma recurrent after a 32 month disease-free survival period. Univariate factors predicting for relapse include tumor burden, immature teratoma with non-term cell elements, and site (mediastinum), whereas only immature teratoma with non-germ cell elements and site predicted for survival. Immature teratoma and mature teratoma had similar relapse-free intervals and overall survival intervals. According to a multivariate analysis, primary tumor site at the mediastinum is the most significant adverse factor predictive for both relapse and survival (two of five patients survived). This study appears to support the various preclinical models that demonstrate multipotential capabilities of teratoma. Complete surgical excision of teratoma remains the most effective treatment with continued close follow-up recommended for high-risk patients (immature teratoma with non-germ cell elements, large tumor burden, or primary mediastinal tumors).

Original languageEnglish
Pages (from-to)676-683
Number of pages8
JournalJournal of Thoracic and Cardiovascular Surgery
Volume92
Issue number4
StatePublished - 1986

Fingerprint

Germ Cell and Embryonal Neoplasms
Teratoma
Cisplatin
Thorax
Drug Therapy
Carcinoma
Recurrence
Mediastinum
Tumor Burden
Survival
Mediastinal Neoplasms
Second Primary Neoplasms
Combination Drug Therapy
Disease-Free Survival
Survivors
Neoplasms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Resection of thoracic and abdominal teratoma in patients after cisplatin-based chemotherapy for germ cell tumor : Late results. / Loehrer, Patrick; Mandelbaum, I.; Hui, Siu; Clark, S.; Einhorn, Lawrence; Williams, S. D.; Donohue, J. P.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 92, No. 4, 1986, p. 676-683.

Research output: Contribution to journalArticle

@article{f40711d93f8c42d1b8fc28ff0c735bdc,
title = "Resection of thoracic and abdominal teratoma in patients after cisplatin-based chemotherapy for germ cell tumor: Late results",
abstract = "Fifty-one patients with primary testicular (N = 46) or mediastinal germ cell cancer (N = 5) were treated from April, 1975, through May, 1981, and had teratoma resected from residual disease after cisplatin-based combination chemotherapy. All patients had normal serum markers before resection of pulmonary (N = 12), mediastinal (N = 5), thoracoabdominal (N = 8), supraclavicular (N = 1) or abdominal disease (N = 25). Teratoma was classified as mature teratoma (N = 29), immature teratoma (N = 15), or immature teratoma with non-germ cell elements (N = 7). Thirty of 51 (60{\%}) patients remain free of recurrent disease, whereas 20 patients have either recurrent carcinoma (N = 10) or teratoma (N = 10). One patient has a presumed second malignancy. After additional chemotherapy, four patients with recurrent carcinoma are alive and disease free and six have died. After an additional operation, eight of 10 patients with recurrent teratoma are long-term survivors. In four patients the initial relapse of carcinoma developed more than 2 years after therapy; in an additional patients carcinoma recurrent after a 32 month disease-free survival period. Univariate factors predicting for relapse include tumor burden, immature teratoma with non-term cell elements, and site (mediastinum), whereas only immature teratoma with non-germ cell elements and site predicted for survival. Immature teratoma and mature teratoma had similar relapse-free intervals and overall survival intervals. According to a multivariate analysis, primary tumor site at the mediastinum is the most significant adverse factor predictive for both relapse and survival (two of five patients survived). This study appears to support the various preclinical models that demonstrate multipotential capabilities of teratoma. Complete surgical excision of teratoma remains the most effective treatment with continued close follow-up recommended for high-risk patients (immature teratoma with non-germ cell elements, large tumor burden, or primary mediastinal tumors).",
author = "Patrick Loehrer and I. Mandelbaum and Siu Hui and S. Clark and Lawrence Einhorn and Williams, {S. D.} and Donohue, {J. P.}",
year = "1986",
language = "English",
volume = "92",
pages = "676--683",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Resection of thoracic and abdominal teratoma in patients after cisplatin-based chemotherapy for germ cell tumor

T2 - Late results

AU - Loehrer, Patrick

AU - Mandelbaum, I.

AU - Hui, Siu

AU - Clark, S.

AU - Einhorn, Lawrence

AU - Williams, S. D.

AU - Donohue, J. P.

PY - 1986

Y1 - 1986

N2 - Fifty-one patients with primary testicular (N = 46) or mediastinal germ cell cancer (N = 5) were treated from April, 1975, through May, 1981, and had teratoma resected from residual disease after cisplatin-based combination chemotherapy. All patients had normal serum markers before resection of pulmonary (N = 12), mediastinal (N = 5), thoracoabdominal (N = 8), supraclavicular (N = 1) or abdominal disease (N = 25). Teratoma was classified as mature teratoma (N = 29), immature teratoma (N = 15), or immature teratoma with non-germ cell elements (N = 7). Thirty of 51 (60%) patients remain free of recurrent disease, whereas 20 patients have either recurrent carcinoma (N = 10) or teratoma (N = 10). One patient has a presumed second malignancy. After additional chemotherapy, four patients with recurrent carcinoma are alive and disease free and six have died. After an additional operation, eight of 10 patients with recurrent teratoma are long-term survivors. In four patients the initial relapse of carcinoma developed more than 2 years after therapy; in an additional patients carcinoma recurrent after a 32 month disease-free survival period. Univariate factors predicting for relapse include tumor burden, immature teratoma with non-term cell elements, and site (mediastinum), whereas only immature teratoma with non-germ cell elements and site predicted for survival. Immature teratoma and mature teratoma had similar relapse-free intervals and overall survival intervals. According to a multivariate analysis, primary tumor site at the mediastinum is the most significant adverse factor predictive for both relapse and survival (two of five patients survived). This study appears to support the various preclinical models that demonstrate multipotential capabilities of teratoma. Complete surgical excision of teratoma remains the most effective treatment with continued close follow-up recommended for high-risk patients (immature teratoma with non-germ cell elements, large tumor burden, or primary mediastinal tumors).

AB - Fifty-one patients with primary testicular (N = 46) or mediastinal germ cell cancer (N = 5) were treated from April, 1975, through May, 1981, and had teratoma resected from residual disease after cisplatin-based combination chemotherapy. All patients had normal serum markers before resection of pulmonary (N = 12), mediastinal (N = 5), thoracoabdominal (N = 8), supraclavicular (N = 1) or abdominal disease (N = 25). Teratoma was classified as mature teratoma (N = 29), immature teratoma (N = 15), or immature teratoma with non-germ cell elements (N = 7). Thirty of 51 (60%) patients remain free of recurrent disease, whereas 20 patients have either recurrent carcinoma (N = 10) or teratoma (N = 10). One patient has a presumed second malignancy. After additional chemotherapy, four patients with recurrent carcinoma are alive and disease free and six have died. After an additional operation, eight of 10 patients with recurrent teratoma are long-term survivors. In four patients the initial relapse of carcinoma developed more than 2 years after therapy; in an additional patients carcinoma recurrent after a 32 month disease-free survival period. Univariate factors predicting for relapse include tumor burden, immature teratoma with non-term cell elements, and site (mediastinum), whereas only immature teratoma with non-germ cell elements and site predicted for survival. Immature teratoma and mature teratoma had similar relapse-free intervals and overall survival intervals. According to a multivariate analysis, primary tumor site at the mediastinum is the most significant adverse factor predictive for both relapse and survival (two of five patients survived). This study appears to support the various preclinical models that demonstrate multipotential capabilities of teratoma. Complete surgical excision of teratoma remains the most effective treatment with continued close follow-up recommended for high-risk patients (immature teratoma with non-germ cell elements, large tumor burden, or primary mediastinal tumors).

UR - http://www.scopus.com/inward/record.url?scp=0023009040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023009040&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 676

EP - 683

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 4

ER -